Naltrexone for the treatment of obesity: review and update.
about
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to dateMaternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthoodCombinations of drugs in the Treatment of Obesity.The effects of opioids and opioid analogs on animal and human endocrine systemsTailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference BehaviorNanoscale effects of ethanol and naltrexone on protein organization in the plasma membrane studied by photoactivated localization microscopy (PALM).Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.Role of Benzodiazepines in the management of agitation due to inappropriate use of naltrexone.GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?Approaches to the pharmacological treatment of obesity.Weight considerations in psychotropic drug prescribing and switching.Drugs to treat obesity: do they work?Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.[Recent progress and novel perspectives on obesity pharmacotherapy].Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity.
P2860
Q27014110-E923567B-E14E-4C91-BBA0-0D78C158DFD6Q28484561-0A2E06CE-BB85-4564-89DD-082FA5F4472FQ33664063-BC849CD7-CA07-49D7-ADF2-33F68428156AQ33779667-93FA9D06-FC7A-43F1-BFB0-030AA83F6B06Q33890570-D9B45E29-CF2F-493F-B9AE-D52CC316A819Q34501087-C434304A-2AEE-48DF-AB45-481E2C0824FBQ35087610-C37B59A9-C7D6-4AA0-90ED-D7E0F3422093Q36059911-CF77D76D-6D67-4697-87E0-FE3D3A17F275Q36987496-0109E772-BD8E-4A5E-8A1B-50AF5346987AQ37213617-50BFA94F-88CD-4092-8A87-3A88038F1F3CQ37831334-48272A01-123D-47CC-BFCD-A3F98C587764Q37960073-3DFB7159-228A-43C6-820D-3664787D90E1Q38151453-4E38E880-F7A7-41AB-8AFA-D8F73729DEE9Q38800281-962F2A1C-413D-4C60-840E-04773F81B939Q38812405-18531111-7C1C-487F-965D-A94EED55CF06Q42881681-74863263-10E7-496D-A989-A7286421B480Q43578699-88B250F8-053C-4BFE-8099-B4F60B53F84E
P2860
Naltrexone for the treatment of obesity: review and update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Naltrexone for the treatment of obesity: review and update.
@en
Naltrexone for the treatment of obesity: review and update.
@nl
type
label
Naltrexone for the treatment of obesity: review and update.
@en
Naltrexone for the treatment of obesity: review and update.
@nl
prefLabel
Naltrexone for the treatment of obesity: review and update.
@en
Naltrexone for the treatment of obesity: review and update.
@nl
P2860
P1476
Naltrexone for the treatment of obesity: review and update.
@en
P2093
Ken Fujioka
Michael William Lee
P2860
P304
P356
10.1517/14656560903048959
P407
P577
2009-08-01T00:00:00Z